title: Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung.
abstract: Recent studies have suggested that bone marrow-derived multipotent mesenchymal stem cells (MSCs) may have therapeutic applications in multiple clinical disorders including myocardial infarction, diabetes, sepsis, and hepatic and acute renal failure. Here, we tested the therapeutic capacity of human MSCs to restore alveolar epithelial fluid transport and lung fluid balance from acute lung injury (ALI) in an ex vivo perfused human lung preparation injured by E. coli endotoxin. Intra-bronchial instillation of endotoxin into the distal airspaces resulted in pulmonary edema with the loss of alveolar epithelial fluid transport measured as alveolar fluid clearance. Treatment with allogeneic human MSCs or its conditioned medium given 1 h following endotoxin-induced lung injury reduced extravascular lung water, improved lung endothelial barrier permeability and restored alveolar fluid clearance. Using siRNA knockdown of potential paracrine soluble factors, secretion of keratinocyte growth factor was essential for the beneficial effect of MSCs on alveolar epithelial fluid transport, in part by restoring amiloride-dependent sodium transport. In summary, treatment with allogeneic human MSCs or the conditioned medium restores normal fluid balance in an ex vivo perfused human lung injured by E. coli endotoxin.
authors.affiliation: Department of Anesthesiology, University of California, San Francisco, CA 94143, USA. leejw@anesthesia.ucsf.edu
authors.forename: Jae W
authors.initials: JW
authors.lastname: Lee
authors.forename: Xiaohui
authors.initials: X
authors.lastname: Fang
authors.forename: Naveen
authors.initials: N
authors.lastname: Gupta
authors.forename: Vladimir
authors.initials: V
authors.lastname: Serikov
authors.forename: Michael A
authors.initials: MA
authors.lastname: Matthay
mesh_terms: D000208:Acute Disease; D000328:Adult; D000584:Amiloride / Q000494:pharmacology; D001826:Body Fluids / Q000378:metabolism; D002478:Cells, Cultured; D017077:Culture Media, Conditioned / Q000494:pharmacology; D004731:Endotoxins; D004926:Escherichia coli / Q000737:chemistry; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000235:genetics / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007958:Leukocyte Count; D008168:Lung / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D055370:Lung Injury / Q000139:chemically induced / Q000601:surgery*; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000378:metabolism*; D008875:Middle Aged; D009504:Neutrophils / Q000473:pathology; D010477:Perfusion; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000378:metabolism; D011654:Pulmonary Edema / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D011994:Recombinant Proteins / Q000494:pharmacology; D026941:Sodium Channel Blockers / Q000494:pharmacology; D014184:Transplantation, Homologous
chemical_list: D017077:Culture Media, Conditioned; D004731:Endotoxins; C496453:FGF7 protein, human; D011994:Recombinant Proteins; D026941:Sodium Channel Blockers; D051523:Fibroblast Growth Factor 7; D000584:Amiloride